Recent advances in the development and use of plasma concentrates.
The consequences of blood donations infected with human immunodeficiency virus, the rapid advances in protein fractionation and the introduction of recombinant DNA technology have revolutionized the range of plasma products available to the clinician. This article reviews these developments and describes recent recommendations on their use.
Soutar
R L
RL
Aberdeen Royal Infirmary.
D001779:Blood Coagulation Factors / Q000600:supply & distribution / Q000627:therapeutic use*; D005591:Chemical Fractionation; D004274:DNA, Recombinant; D015658:HIV Infections / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D006467:Hemophilia A / Q000150:complications / Q000453:epidemiology / Q000628:therapy; D006801:Humans; D017053:Infection Control / Q000379:methods*; D010952:Plasma Substitutes / Q000600:supply & distribution / Q000627:therapeutic use*; D012106:Research; D006113:United Kingdom / Q000453:epidemiology
D001779:Blood Coagulation Factors; D004274:DNA, Recombinant; D010952:Plasma Substitutes